[Click eStock] "Raizeroptek, Export Increase Expected"

Hana Securities forecasted on the 27th that Palas Premium by LaserOptek will enter the U.S. market in the second half of this year.

Kim Doohyun, a researcher at Hana Securities, stated, "The equipment to pay attention to is Palas Premium, an upgraded version of the Palas device used for vitiligo treatment," and explained, "Palas Premium has improved pulse repetition rate and spot size compared to the existing model, making the treatment speed up to 5 times faster."

He added, "While the existing equipment was slower compared to U.S. competitors, this has been improved," and "Since the response in the U.S. market is positive, sales are expected to increase this year."

LaserOptek is estimated to achieve sales of 44.8 billion KRW and an operating profit of 7.8 billion KRW this year, representing increases of 34.1% and 73.3% respectively compared to last year. Researcher Kim emphasized, "The Palas Premium device, a disease treatment device that received U.S. FDA approval in March last year, will drive performance improvement," and added, "Exports of the aesthetic medical devices Helios 785 and Piccolo Premium are also increasing."